Airway inflammation measurement receives reimbursement in Czech Republic

Airway inflammation measurement receives reimbursement in Czech Republic 

SOLNA, Sweden - 8 April, 2008 - Aerocrine AB (OMX Nordic Exchange: AERO) today
announced that a new reimbursement code has been issued for the exhaled NO tests
in the Czech healthcare system.

Healthcare providers using exhaled Nitric Oxide (NO) to measure airway
inflammation, the root cause of asthma, will receive payment of €13.50 per test
from April 2008. The reimbursement (code 27270) allows physicians to use exhaled
NO tests to more accurately diagnose patients with asthma and to better control
their asthma symptoms.

The use of anti-inflammatory therapy, such as inhaled corticosteroids, forms a
cornerstone in asthma treatment. Inflammation monitoring made possible by
exhaled nitric oxide measurements allows care providers to predict drug
response. The test can also be used to monitor the effects of treatment and to
adjust to the correct dose. A rise in the exhaled NO value may indicate that the
patient is not adhering to the prescribed anti-inflammatory treatment or that
the disease is worsening. By regular monitoring of airway inflammation through
exhaled NO measurements, the management and care of asthma patients may be
dramatically improved, which in turn leads to more cost effective treatment.
 
Aerocrine's NIOX MINO® Airway Inflammation Monitor permits non-invasive, quick
and easy-to-perform eNO measurements. 

For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 82


About Aerocrine
Aerocrine AB is a medical technology company focused on the improved management
and care of patients with inflammatory airway diseases. As the pioneer and
leader in the technology to monitor and manage airway inflammation, Aerocrine
markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable
management of airway inflammation and may therefore play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm
Stock Exchange on 15 June 2007.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act. The information was submitted for publication at
8.00 am on March the 8th 2008.